BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 30352608)

  • 1. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers.
    Ding XP; Zhang J; Li BS; Li HS; Wang ZT; Yi Y; Sun HF; Wang DQ
    Asian Pac J Cancer Prev; 2012; 13(1):319-23. PubMed ID: 22502693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
    Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
    Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
    Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by
    Vera P; Thureau S; Chaumet-Riffaud P; Modzelewski R; Bohn P; Vermandel M; Hapdey S; Pallardy A; Mahé MA; Lacombe M; Boisselier P; Guillemard S; Olivier P; Beckendorf V; Salem N; Charrier N; Chajon E; Devillers A; Aide N; Danhier S; Denis F; Muratet JP; Martin E; Riedinger AB; Kolesnikov-Gauthier H; Dansin E; Massabeau C; Courbon F; Farcy Jacquet MP; Kotzki PO; Houzard C; Mornex F; Vervueren L; Paumier A; Fernandez P; Salaun M; Dubray B
    J Nucl Med; 2017 Jul; 58(7):1045-1053. PubMed ID: 28254869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
    Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
    Nkhali L; Thureau S; Edet-Sanson A; Doyeux K; Benyoucef A; Gardin I; Michel P; Vera P; Dubray B
    Acta Oncol; 2015 Jun; 54(6):909-15. PubMed ID: 25417733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry study of
    Li H; Xu D; Han X; Ruan Q; Zhang X; Mi Y; Dong M; Guo S; Lin Y; Wang B; Li G
    Clin Transl Oncol; 2018 Oct; 20(10):1329-1336. PubMed ID: 29623584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.
    Even AJ; van der Stoep J; Zegers CM; Reymen B; Troost EG; Lambin P; van Elmpt W
    Radiother Oncol; 2015 Aug; 116(2):281-6. PubMed ID: 26238010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.
    Lee E; Zeng J; Miyaoka RS; Saini J; Kinahan PE; Sandison GA; Wong T; Vesselle HJ; Rengan R; Bowen SR
    Med Phys; 2017 Jul; 44(7):3418-3429. PubMed ID: 28453861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
    Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.